Published in Comput Math Methods Med on March 23, 2011
Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol (2013) 1.05
Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today (2014) 0.90
Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data. Phys Med Biol (2012) 0.81
Integrated PK-PD and agent-based modeling in oncology. J Pharmacokinet Pharmacodyn (2015) 0.79
Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol (2013) 0.78
Cell-oriented modeling of angiogenesis. ScientificWorldJournal (2011) 0.76
Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS One (2015) 0.76
A novel method for simulating the extracellular matrix in models of tumour growth. Comput Math Methods Med (2012) 0.76
Mathematical Based Calculation of Drug Penetration Depth in Solid Tumors. Biomed Res Int (2016) 0.75
Modelling tumour volume variations in head and neck cancer: magnetic resonance imaging contribution for patients undergoing induction chemotherapy. Acta Otorhinolaryngol Ital (2016) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) (2006) 4.84
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A (2000) 3.69
Fundamental concepts of the angiogenic process. Curr Mol Med (2003) 3.16
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Adaptive therapy. Cancer Res (2009) 2.81
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg (2009) 2.66
Vascular targeting agents as cancer therapeutics. Clin Cancer Res (2004) 2.43
Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol (2008) 2.13
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 2.12
Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol (2006) 2.09
Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol (2000) 1.94
A change of strategy in the war on cancer. Nature (2009) 1.92
Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Bull Math Biol (2005) 1.91
Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov (2004) 1.88
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies. Bull Math Biol (2002) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Biomed Microdevices (2004) 1.29
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26
A novel three-phase model of brain tissue microstructure. PLoS Comput Biol (2008) 1.16
Modeling the effects of vasculature evolution on early brain tumor growth. J Theor Biol (2006) 1.12
A spatial model of tumor-host interaction: application of chemotherapy. Math Biosci Eng (2009) 1.10
Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci (2003) 1.04
Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. J Theor Biol (2008) 1.02
Simulating tumor growth in confined heterogeneous environments. Phys Biol (2008) 1.00
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep (2005) 0.98
A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. Bull Math Biol (2005) 0.98
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy (2004) 0.93
Growing heterogeneous tumors in silico. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 0.89
Regression and regrowth of tumour cords following single-dose anticancer treatment. Bull Math Biol (2003) 0.89
Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput Biomed Res (2000) 0.88
Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model. Comput Biol Med (2001) 0.87
VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release (2001) 0.86
The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture. Neurol Res (2003) 0.82
Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity. Math Biosci (1995) 0.80
Numerical simulation of a stochastic model for cancerous cells submitted to chemotherapy. J Math Biol (1989) 0.79
Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs. IMA J Math Appl Med Biol (1996) 0.78
Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy. IMA J Math Appl Med Biol (2000) 0.77